8-K: Relay Therapeutics Announces Positive RLY-2608 Data and Q3 2024 Financial Results

Relay Therapeutics reported encouraging interim data for RLY-2608 in breast cancer and a strong cash position, while also streamlining operations.

Summary

• Relay Therapeutics announced its third quarter 2024 financial results and provided updates on its clinical programs.
• The company reported positive interim data for RLY-2608 in heavily pre-treated patients with PI3K-mutated, HR+/HER2metastatic breast cancer, showing a 9.2-month median progression-free survival (PFS).
• A pivotal trial for RLY-2608 in second-line breast cancer is planned for 2025.
• Relay Therapeutics has approximately $840 million in cash, cash equivalents, and investments, which is expected to fund operations into the second half of 2027.
• The company raised $230 million through a follow-on public offering in September 2024.
• Relay Therapeutics is streamlining its research organization, expecting $50 million in annual savings and a 15% workforce reduction.
• Third quarter revenue was $0, compared to $25.2 million in the same period last year, due to the absence of milestone payments.
• Research and development expenses decreased to $76.6 million from $81.5 million year-over-year.
• The net loss for the quarter was $88.1 million, or $0.63 per share, compared to a net loss of $65.7 million, or $0.54 per share, in the third quarter of 2023.

Sentiment

Score: 8

Explanation: The document presents positive clinical data, a strong cash position, and cost-saving measures, indicating a positive outlook for the company. However, the increased net loss and lack of revenue in the quarter temper the overall sentiment slightly.

Positives

• The interim data for RLY-2608 shows promising clinical efficacy with a 9.2-month median PFS in a difficult-to-treat patient population.
• The company has a strong cash position of approximately $840 million, providing a runway into the second half of 2027.
• The planned pivotal trial for RLY-2608 in 2025 is a significant step towards potential commercialization.
• The streamlining of the research organization is expected to result in substantial cost savings of $50 million annually.
• The company is advancing multiple clinical programs and expects to bring new programs into the clinic in 2025.

Negatives

• Third quarter revenue was $0, a significant decrease from $25.2 million in the same period last year.
• The net loss for the quarter increased to $88.1 million from $65.7 million year-over-year.
• The workforce reduction of approximately 15% may impact morale and productivity.
• The company is seeking a global commercialization partner for lirafugratinib, indicating a shift in focus and potentially reduced control over this asset.

Risks

• The company's clinical trials may not be successful, and the preliminary results may not be predictive of future outcomes.
• Regulatory approvals for RLY-2608 and other drug candidates are not guaranteed.
• The company's ability to maintain and protect its intellectual property is crucial.
• The company's financial performance is dependent on the success of its clinical programs and the ability to secure partnerships.
• Global economic uncertainty, geopolitical instability, and public health issues could impact the company's operations and financial results.

Future Outlook

Relay Therapeutics expects its current cash to fund operations into the second half of 2027 and plans to initiate a pivotal trial for RLY-2608 in 2025. The company also anticipates bringing new programs into the clinic in 2025.

Management Comments

• Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics, stated that the interim data for RLY-2608 + fulvestrant showed clinically meaningful progression-free survival in heavily pre-treated patients.
• Management believes they can fully fund the pivotal trial through top-line readout with existing cash on hand.

Industry Context

The positive data for RLY-2608 in breast cancer positions Relay Therapeutics as a potential competitor in the targeted oncology space. The company's focus on precision medicine and the use of computational and experimental technologies aligns with current industry trends in drug discovery.

Comparison to Industry Standards

• The 9.2-month median PFS for RLY-2608 in heavily pre-treated patients is competitive with other targeted therapies in the same space, such as PI3K inhibitors like alpelisib (Piqray) which has shown similar PFS results in combination with fulvestrant.
• The 53% ORR in patients with kinase mutations at the RP2D is a strong result compared to other treatments in this patient population.
• Relay's cash runway into the second half of 2027 is a positive sign of financial stability compared to other clinical-stage biotech companies that often face funding challenges.
• The company's focus on streamlining operations and reducing costs is a common practice in the biotech industry to ensure efficient use of capital.

Stakeholder Impact

• Shareholders may view the positive clinical data and strong cash position favorably.
• Employees may be impacted by the workforce reduction of approximately 15%.
• Patients may benefit from the potential approval of RLY-2608.
• Partners may be interested in the opportunity to collaborate on the commercialization of lirafugratinib.

Next Steps

• Initiate a pivotal trial of RLY-2608 + fulvestrant in 2L breast cancer in 2025.
• Present RLY-2608 data at the San Antonio Breast Cancer Symposium in December 2024.
• Initiate RLY-2608 + atirmociclib + fulvestrant clinical trial by the end of 2024.
• Initiate RLY-2608 + fulvestrant + ribociclib dose expansion cohorts in the first half of 2025.
• Initiate clinical trials for RLY-2608 in vascular malformations in the first quarter of 2025.
• Initiate clinical trials for Fabry disease and NRAS programs in the second half of 2025.
• Seek a global commercialization partner for lirafugratinib.

Key Dates

Keywords

RLY-2608, breast cancer, PI3K inhibitor, clinical trial, precision medicine, financial results, cash runway, drug development, oncology, lirafugratinib